Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination ...

In this interview, Mark C. Markowski, MD, PhD, discusses bipolar androgen therapy (BAT), including its advantages and disadvantages, trials that have evaluated the treatment, and what some next steps ...

Using the PhalloFILL system, a novel hyaluronic acid filler, appeared to be safe when administered for penile girth enhancement, according to a retrospective review presented at the 24th Annual Fall ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Aquablation therapy demonstrated strong efficacy and safety vs transurethral resection of the prostate (TURP) for the treatment of men with lower urinary tract symptoms (LUTS) related to benign ...

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

Specifically, the bill cuts funding for CDMRP from $1.509 billion in FY2024 to $650 million in FY2025. Prostate and kidney cancer research is currently funded at $110 million and $50 million, ...

Conversion factor (CF): The CF for 2025 is proposed to decrease to $32.36 from $33.29 in 2024. This is a decrease of 2.80%. This decrease is due to several factors, but mainly the expiration of a ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

In this interview, Arpeet Shah, MD, considers some of the advancements and challenges that the field of urology will face in the coming year.Shah is a urologist at Associated Urological Specialists, ...

In this interview, Nedim Ruhotina, MD, outlines currently available as well as promising up-and-coming biomarkers for advanced prostate cancer. Dr Ruhotina is a urologist with Associated Medical ...

In this interview, Patrick Soon-Shiong, MD, shares key updates in the development of nogapendekin alfa inbakicept-pmln (Anktiva), which was approved by the FDA in April 2024 for patients with ...